Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2026-02-23 @ 6:25 AM
Study NCT ID:
NCT06716658
Status:
RECRUITING
Last Update Posted:
2025-11-18
First Post:
2024-11-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Lymphoma, T-Cell | View |
| None | NK-LGL Leukemia | View |
| None | T-LGL Leukemia | View |
| None | Cutaneous T Cell Lymphoma | View |
| None | Cutaneous T Cell Lymphoma (CTCL) | View |
| None | Large Granular Lymphocyte Leukemia | View |
| None | Large Granular Lymphocytic Leukemia | View |
| None | Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract | View |
| None | Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma | View |
| None | Mycosis Fungoides | View |